Concerns about overseas inspections continue in the wake of an HHS plan to create 2 potential pathways to allow the importation of some drugs that were intended for foreign markets.
In a letter to HHS Secretary Alex Azar and FDA Acting Commissioner Norman Sharpless, MD, last week, Sen. Chuck Grassley, R-Iowa, asked the FDA to perform more unannounced inspections of foreign drug manufacturing facilities.
Grassley first wrote to the FDA about the issue at the end of June, but now says he has learned that the FDA does not track in its databases whether a foreign inspection was subject to an announced or unannounced visit.
He is also concerned that typically, the FDA does not perform unannounced visits of drug manufacturing facilities in foreign countries.
The concern takes on new urgency since last month, when HHS announced its Safe Importation Action Plan, a document outlining 2 potential pathways to allow the importation of some drugs that were intended for foreign markets.
Grassley said that while 80% of active ingredients used in pharmaceuticals are made abroad (mostly in China and India), the FDA inspected 1 in 5 registered human drug manufacturing sites in other countries last year.
“I strongly encourage the administration’s demonstration projects to include unannounced inspections in foreign manufacturing facilities to determine whether they meet the required Active Pharmaceutical Ingredients and drug quality and safety standards to include sufficient record-keeping, testing and protections against counterfeiting,” he wrote.
This letter comes after a previous letter on the topic sent to Azar and Sharpless in June, where he sought information on the quality controls for prescription drugs and their components made in foreign countries, and also asked what the FDA is doing to uphold safety standards in the United States, China, and India through inspections.
The concern is bipartisan: In a related issue, in June the House Energy and Commerce Chairman Frank Pallone, Jr., D-New Jersey, asked the FDA for updated information on the agency’s inspections of imported cosmetic products. Pallone said he was alarmed that the agency has not conducted any foreign cosmetic inspections in fiscal year (FY) 2019 and does not intend to conduct any inspections in FY 2020.
In 2017, the General Accounting Office issued a report about the FDA’s inspection program, particularly staffing issues related to fill its China and India-based offices. In June and July of 2018 the FDA said the vacancy rate in foreign offices had fallen to 15% from 46% in 2016 and that it had developed new performance measures for these offices, along with a monitoring and evaluation plan.
Grassley, however, still questioned in his latest letter why a 2013 FDA pilot program in India “that eliminated advanced notice and instead used short notice or unannounced visits” was “shut down without explanation” in 2015. He said the pilot “exposed widespread malfeasance” that had otherwise been hidden because of a previous system that allowed advanced warnings for manufacturing sites.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.